stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Revenue
Prestige Consumer Healthcare Inc.'s revenue for fiscal 2026 was $1.1B, unchanged from fiscal 2025. Over the twelve months to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $714.6M (fiscal 2015) to $1.1B (fiscal 2025); the current reading is higher than 75% of that period. Prestige Consumer Healthcare Inc. ranks 18th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $1.1B | (4.31%) |
| FY2025 | $1.1B | 1.10% |
| FY2024 | $1.1B | (0.21%) |
| FY2023 | $1.1B | 3.76% |
| FY2022 | $1.1B | 15.21% |
| FY2021 | $943.4M | (2.04%) |
| FY2020 | $963.0M | (1.31%) |
| FY2019 | $975.8M | (6.28%) |
| FY2018 | $1.0B | 18.04% |
| FY2017 | $882.1M | 9.40% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $336.3M | 26.57% |
| Jun 2026 | $265.7M | (5.65%) |
| Mar 2026 | $281.6M | (0.64%) |
| Dec 2025 | $283.4M | 3.40% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| PBH Prestige Consumer Healthcare Inc. | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. compare | $368.3M |
| ALVO Alvotech compare | $293.3M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PBH
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement